Dr. Bob Langer is the recipient of numerous prestigious awards in engineering, including the Charles Stark Draper Prize, often referred to as the “Nobel Prize for Engineering,” and the Queen Elizabeth Prize for Engineering. He is the only person to have won both awards individually. He has also received the National Medal of Science and the […]
Dr. Greg Nowakowski is Head of the Early Development Organization at Daiichi Sankyo, where he leads the company’s global oncology and non-oncology development portfolio and oversees early clinical science, translational strategy, clinical development, predictive biomarkers, regulatory strategy, and the transition from early- to late-stage programs. He previously served as Professor of Medicine and Oncology and Deputy […]
Dr. Diane Mould is a Fellow of the American College of Clinical Pharmacology and the American Association of Pharmaceutical Sciences, with extensive contributions to pharmacometrics and model-based drug development. She serves on the editorial boards of the Journal of Pharmacokinetics and Pharmacodynamics, Clinical Pharmacology and Therapeutics, and the Journal of Clinical Pharmacology, and sits on the […]
Dr. Michael Maitland is an internationally recognized physician-scientist specializing in the early-phase development of novel therapies. He most recently served as Vice President, Clinical Development at Pathos AI, and before that as Medical Lead for CRISPR-based therapies, including lonvoguran ziclumeran (NTLA-2002) and nexiguran ziclumeran (NTLA-2001), at Intellia Therapeutics. He has founded and continues to lead multiple […]
Dr. Andrew Pecora is the founder and former director of the John Thauer Comprehensive Cancer Center, an NCI-designated cancer care facility in New Jersey. An internationally recognized expert in cellular therapy and cancer immunology, he has played a role in many of the field’s pivotal studies, including the positive Phase 3 INTerpath-001 trial, which confirmed the […]